礼来公司 (Eli Lilly) 的体重管理药物 Zepbound 的表现优于 Wegovy，潜在的亚马逊药房合作伙伴关系促进了销售，并使礼来公司的股票具有吸引力。 Eli Lilly's weight management drug Zepbound outperforms Wegovy, with potential Amazon Pharmacy partnership boosting sales and making Lilly stock attractive.

礼来公司 (Eli Lilly) 的体重管理药物 Zepbound 显示出可喜的销售增长，超过了诺和诺德 (Novo Nordisk) 的 Wegovy。 Eli Lilly's Zepbound, a weight management drug, shows promising sales growth, outpacing Novo Nordisk's Wegovy. 与亚马逊药房的合作可能会进一步促进销售。 A partnership with Amazon Pharmacy may further boost sales. 此次合作可能使礼来股票成为明智的买入选择，因为该公司最新的体重管理药物替泽帕肽（Mounjaro）在糖尿病治疗市场表现良好。 This collaboration could make Eli Lilly stock a smart buy, as the company's newest weight management treatment, tirzepatide (Mounjaro), has performed well in the diabetes treatment market.